Nanoparticles Take Aim at Bladder Infections, Catheter Biofilms and Chronic Pelvic Pain

Inflammatory disorders of the urinary system are among the most stubborn problems in modern medicine. Urinary tract infections alone strike roughly 150 million people every year, and about three-quarters of hospital-acquired cases are tied to urinary catheterization. Beyond infection, conditions such as interstitial cystitis/bladder pain syndrome, which affects an estimated 2.7 to 6.5 percent of adult women in the United States, and chronic prostatitis/chronic pelvic pain syndrome, which touches 2 to 10 percent of men worldwide, impose chronic suffering that conventional drugs only partially relieve. A comprehensive review published in Materials Today Bio now maps out how nanoparticle-based platforms, spanning organic carriers, inorganic nanomaterials and hybrid composites, could reconfigure local therapy for these diseases by engineering drug delivery, regulating biological interfaces and triggering release only where inflammation rages.

The core problem the review identifies is not a shortage of drugs but a failure of delivery. In urinary tract infection, uropathogenic Escherichia coli adheres to the bladder lining through adhesins such as FimH, invades epithelial cells and builds intracellular bacterial communities that shelter it from antibiotics and immune attack. Catheter-associated infections add another layer: proteins from urine rapidly coat the device surface, forming a conditioning film on which pathogens such as Enterococcus faecalis construct mature biofilms whose extracellular matrix blocks drug diffusion and harbors metabolically quiescent bacteria. Meanwhile, continuous urine washout, cyclic bladder filling and emptying, and the urothelial mucus barrier strip away free drugs before they can act. For interstitial cystitis and chronic prostatitis, the barriers are anatomical: the prostatic capsule, epithelial tight junctions and local microcirculation restrict penetration, while heterogeneous, multifactorial pathology limits oral medications to symptomatic relief.

Nanoparticles attack these bottlenecks through tunable physics. By adjusting particle size, surface charge, material composition and surface ligands, researchers can boost drug loading, prolong local retention, enhance tissue penetration and program controlled release. The review divides the relevant platforms into three classes. Organic nanoparticles, including liposomes, polymeric particles, dendrimers and chitosan, offer biocompatibility, biodegradability and flexible loading, making them well suited to intravesical instillation, mucosal adhesion and delivery of proteins or nucleic acids. Inorganic nanoparticles, such as silver, gold, copper and zinc oxide particles and mesoporous silica, bring intrinsic antibacterial, antioxidant, photothermal or imaging capabilities that do not depend on traditional antibiotic targets. Hybrid systems combine the two, integrating drug delivery, contact killing, anti-adhesive surfaces and sustained release within a single construct.

For recurrent urinary tract infection, the most striking advance targets bacteria hiding inside bladder cells. Tetracycline loaded onto bovine serum albumin-coated nanodiamonds was taken up by urothelial cells, colocalized with intracellular UPEC and released its cargo in acidic endosomes, enhancing bacterial clearance, reducing bladder inflammation and shrinking residual intracellular bacterial communities in infected bladders. Elsewhere, rosemary-oil-loaded chitosan nanophytosomes boosted antibacterial and antibiofilm activity against multidrug-resistant E. coli while easing tissue injury, and liposomes have been shown to protect piperacillin from destruction by staphylococcal beta-lactamase, preserving activity against enzyme-mediated resistance. Ciprofloxacin carried in albumin nanoparticles retained anti-UPEC activity with reduced toxicity to bladder cells and greater effect against mature biofilms than the free drug.

Inorganic nanomaterials bring multimodal killing mechanisms to the fight. Silver nanoparticles release silver ions, generate reactive oxygen species, disrupt membranes and interfere with DNA replication, retaining activity against many drug-resistant strains. Green-synthesized silver particles derived from betel-leaf extract have been shown to silence quorum-sensing systems in Serratia marcescens and Proteus mirabilis, downregulating virulence and biofilm genes. Combining silver nanoparticles with ampicillin or amikacin produced synergistic effects against multidrug-resistant uropathogens at concentrations with low toxicity to human fibroblasts. Zinc oxide nanoparticles inhibited adhesion of fluconazole-resistant Candida albicans by downregulating the ALS1 and ALS3 genes, while silica-tannase nanoconjugates outperformed conventional antibiotics against common urinary pathogens in vitro.

Catheter-associated infection has emerged as the clearest engineering application. A dual-layer nanoengineered catheter deposited silver nanoparticles on silicone and capped them with porous zinc, which regulated ion release, curbed burst effects and, through zinc-mediated reactive oxygen generation, blocked early bacterial adhesion; in a rabbit model it reduced biofilm, encrustation, urethral inflammation and epithelial injury. Beta-casein-capped hollow chitosan nanospheres co-loading a quorum-sensing inhibitor and a bactericide released their payloads sequentially in response to bacterial proteases, suppressing biofilm formation by more than 95 percent and preventing catheter occlusion for 30 days in artificial urine flow. Gold nanoshells immobilized on silicone generated localized heat under near-infrared irradiation, eradicating adherent drug-resistant E. faecalis, while zinc-doped copper oxide coatings delayed the onset of catheter-associated infection in rabbits, with some animals remaining infection-free throughout a seven-day experiment.

Hybrid and biomimetic coatings push the concept further. A superhydrophobic polydopamine-silver-perfluorinated multilayer on silicone catheters combined reduced bacterial contact, delayed biofilm formation and sustained silver release, extending the time to catheter obstruction from roughly 40 hours to about 100 hours. A nanozyme hydrogel built from gold and iron co-doped silver peroxide paired peroxidase-like catalytic hydroxyl radical generation with catalase-like oxygen production, adding anti-inflammatory and microenvironmental modulation to antibacterial action. Biodegradable ureteral stents embedded with silver-gold core-shell nanoparticles created a constantly renewing contact-killing surface that reduced stent-associated infection in a porcine model, illustrating how device interfaces can be engineered for long-term protection.

For noninfectious disease, the emphasis shifts from killing bacteria to repairing barriers and calming chronic inflammation. Thiolated chitosan nanoparticles formed disulfide bonds with bladder mucosal glycoproteins, achieving roughly 14-fold greater adhesion than unmodified particles under urine washout. Cationic liposomes delivered nerve growth factor antisense oligonucleotides to the urothelium with about 40-fold higher uptake than free oligonucleotides, normalizing voiding frequency in a rat model of interstitial cystitis. Hyaluronic acid-based self-assembled nanosheets replenished the damaged glycosaminoglycan layer and reduced bladder inflammation, while curcumin-loaded cerium oxide nanoparticles exploited the reversible cerium redox cycle to scavenge reactive oxygen species, easing pain and restoring urothelial integrity in mice. A nerve-growth-factor-targeting nanocluster-antibody-drug conjugate even combined lesion targeting, fluorescence and CT imaging and immunomodulatory drug release, outperforming standard intravesical therapies in preclinical models.

Chronic prostatitis/chronic pelvic pain syndrome illustrates the precision potential most vividly. Folate-modified, oxidation-responsive nanoparticles loaded with cefpodoxime proxetel homed to folate receptors on activated macrophages in inflamed prostatic tissue, released antibiotic in the reactive-oxygen-rich environment while consuming excess radicals, and reduced bacterial burden, inflammatory cytokines and pelvic pain sensitization in mice. A pH and ROS dual-responsive dexamethasone nanoformulation accumulated in prostatic tissue, attenuated pelvic pain hypersensitivity and was associated with reduced depression-like behavior. Antigen-coupled PLGA nanoparticles carrying a TRPM8-derived peptide induced immune tolerance, raising pain thresholds and lowering inflammatory markers, a strategy fundamentally distinct from conventional analgesia.

The authors are careful to temper enthusiasm with translational reality. Most evidence remains confined to cell cultures and short-term animal studies whose models poorly capture chronicity, recurrence and patient heterogeneity. Long-term safety questions loom large, particularly for metal-based nanomaterials where the window between bacterial killing and urothelial injury must be defined, and for biomimetic systems where donor variability complicates quality control. Manufacturing scale-up, batch consistency, storage stability and premature drug leakage all demand systematic standards. Yet the trajectory is clear: from simple antibiotic carriers toward multifunctional, stimuli-responsive, phenotype-matched platforms that could one day pair with antibiotics, behavioral therapy and neuromodulation as components of individualized care for some of urology’s most persistent inflammatory diseases.

Subject of Research: Nanoparticle-based therapeutic platforms for inflammatory disorders of the urinary system, including urinary tract infection, catheter-associated infection, interstitial cystitis/bladder pain syndrome and chronic prostatitis/chronic pelvic pain syndrome

Article Title: Nanoparticle-based therapeutic platforms for inflammatory disorders of the urinary system: Engineering local delivery, biointerface regulation, and smart responsive therapy

Article References: Wang, W., Ma, J., Hou, C., Chen, J., & Ni, K. (2026). Nanoparticle-based therapeutic platforms for inflammatory disorders of the urinary system: Engineering local delivery, biointerface regulation, and smart responsive therapy. Materials Today Bio, 41, Article 103673. https://doi.org/10.1016/j.mtbio.2026.103673

Image Credits: AI Generated

DOI: 10.1016/j.mtbio.2026.103673

Keywords: nanoparticles, urinary tract infection, catheter-associated UTI, interstitial cystitis, chronic prostatitis, biofilms, drug delivery, silver nanoparticles, stimuli-responsive release, intravesical therapy, antimicrobial resistance, nanomedicine